logo
Plus   Neg
Share
Email

PerkinElmer To Acquire Oxford Immunotec - Quick Facts

PerkinElmer, Inc. (PKI) and Oxford Immunotec Global PLC (OXFD) have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec. Oxford shareholders will be entitled to receive $22.00 in cash for each outstanding ordinary share. This value the company's entire issued and to be issued ordinary share capital at approximately $591 million.

Headquartered in Abingdon, UK, Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis.

PerkinElmer anticipates the deal to be modestly accretive to non-GAAP earnings in year-one following the close.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
Follow RTT